Cargando…

Riluzole Stimulates BDNF Release from Human Platelets

Brain-derived neurotrophic factor (BDNF) has several functions in the central nervous system, where it contributes to brain development and its functionality through affecting neuronal survival and activity and also modulating neurotransmitter levels. This neurotrophin is also found in the serum, bu...

Descripción completa

Detalles Bibliográficos
Autores principales: Türck, Patrick, Frizzo, Marcos Emílio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4300019/
https://www.ncbi.nlm.nih.gov/pubmed/25629040
http://dx.doi.org/10.1155/2015/189307
_version_ 1782353468922527744
author Türck, Patrick
Frizzo, Marcos Emílio
author_facet Türck, Patrick
Frizzo, Marcos Emílio
author_sort Türck, Patrick
collection PubMed
description Brain-derived neurotrophic factor (BDNF) has several functions in the central nervous system, where it contributes to brain development and its functionality through affecting neuronal survival and activity and also modulating neurotransmitter levels. This neurotrophin is also found in the serum, but its origin and peripheral function remain unknown. Although the source of circulating BDNF is uncertain, it is stored in platelets and can be released through pharmacological treatment. Decreased levels of BDNF in the serum have been related to the pathophysiology of depression, and this relationship is reinforced by the reversal of this condition by treatment with antidepressants. Recently, riluzole has been proposed for the treatment of depression because it has the ability to lower extracellular glutamate levels and increase BDNF expression; and both mechanisms could be associated with its antidepressant action. Considering that riluzole enhances BDNF levels in the serum of patients, we investigated if treatment with this drug could stimulate the release of this neurotrophin from human platelets obtained from healthy subjects. When platelets were incubated with riluzole for 4 h, the basal value of BDNF (92.9 ± 11.1 pg 10(−6) platelets) was significantly increased (P < 0.05, n = 27). This stimulatory effect was achieved at low concentrations of riluzole (from 10 µM) and was not observed when platelets were incubated with the drug for 24 h. The direct action of riluzole evoking BDNF release from human platelets at therapeutic concentrations is important and may contribute to the understanding of its mechanisms of action in the treatment of depression.
format Online
Article
Text
id pubmed-4300019
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-43000192015-01-27 Riluzole Stimulates BDNF Release from Human Platelets Türck, Patrick Frizzo, Marcos Emílio Biomed Res Int Research Article Brain-derived neurotrophic factor (BDNF) has several functions in the central nervous system, where it contributes to brain development and its functionality through affecting neuronal survival and activity and also modulating neurotransmitter levels. This neurotrophin is also found in the serum, but its origin and peripheral function remain unknown. Although the source of circulating BDNF is uncertain, it is stored in platelets and can be released through pharmacological treatment. Decreased levels of BDNF in the serum have been related to the pathophysiology of depression, and this relationship is reinforced by the reversal of this condition by treatment with antidepressants. Recently, riluzole has been proposed for the treatment of depression because it has the ability to lower extracellular glutamate levels and increase BDNF expression; and both mechanisms could be associated with its antidepressant action. Considering that riluzole enhances BDNF levels in the serum of patients, we investigated if treatment with this drug could stimulate the release of this neurotrophin from human platelets obtained from healthy subjects. When platelets were incubated with riluzole for 4 h, the basal value of BDNF (92.9 ± 11.1 pg 10(−6) platelets) was significantly increased (P < 0.05, n = 27). This stimulatory effect was achieved at low concentrations of riluzole (from 10 µM) and was not observed when platelets were incubated with the drug for 24 h. The direct action of riluzole evoking BDNF release from human platelets at therapeutic concentrations is important and may contribute to the understanding of its mechanisms of action in the treatment of depression. Hindawi Publishing Corporation 2015 2015-01-06 /pmc/articles/PMC4300019/ /pubmed/25629040 http://dx.doi.org/10.1155/2015/189307 Text en Copyright © 2015 P. Türck and M. E. Frizzo. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Türck, Patrick
Frizzo, Marcos Emílio
Riluzole Stimulates BDNF Release from Human Platelets
title Riluzole Stimulates BDNF Release from Human Platelets
title_full Riluzole Stimulates BDNF Release from Human Platelets
title_fullStr Riluzole Stimulates BDNF Release from Human Platelets
title_full_unstemmed Riluzole Stimulates BDNF Release from Human Platelets
title_short Riluzole Stimulates BDNF Release from Human Platelets
title_sort riluzole stimulates bdnf release from human platelets
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4300019/
https://www.ncbi.nlm.nih.gov/pubmed/25629040
http://dx.doi.org/10.1155/2015/189307
work_keys_str_mv AT turckpatrick riluzolestimulatesbdnfreleasefromhumanplatelets
AT frizzomarcosemilio riluzolestimulatesbdnfreleasefromhumanplatelets